DUBLIN–(BUSINESS WIRE)–The “Systemic Lupus Erythematosus (Sle) Drugs – Global Market Trajectory & Analytics” report has been added to ResearchAndMarkets.com’s offering.

Global Systemic Lupus Erythematosus (Sle) Drugs Market to Reach US$264.5 Million by the Year 2027

Amid the COVID-19 crisis, the global market for Systemic Lupus Erythematosus (Sle) Drugs estimated at US$183.3 Million in the year 2020, is projected to reach a revised size of US$264.5 Million by 2027, growing at a CAGR of 5.4% over the period 2020-2027.

The U. S. Accounts for Over 29.5% of Global Market Size in 2020, While China is Forecast to Grow at a 5% CAGR for the Period of 2020-2027

The Systemic Lupus Erythematosus (Sle) Drugs market in the U. S. is estimated at US$54 Million in the year 2020. The country currently accounts for a 29.48% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$46. (Read more…)6 Million in the year 2027 trailing a CAGR of 5% through 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.1% and 4.3% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.4% CAGR while Rest of European market (as defined in the study) will reach US$46.6 Million by the year 2027.

The report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.

Competitors identified in this market include, among others:

• Amgen, Inc.
• Bristol-Myers Squibb Company
• GlaxoSmithKline PLC
• Immunomedics, Inc.
• Johnson & Johnson
• MedImmune LLC
• Merck Serono GmbH
• Sanofi SA
• Teva Pharmaceutical Industries Ltd.
• UCB SA

Key Topics Covered:

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

• Impact of Covid-19 and a Looming Global Recession
• Global Competitor Market Shares
• Systemic Lupus Erythematosus (Sle) Drugs Competitor Market Share Scenario Worldwide (in %): 2018E

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

• World Current & Future Analysis for Systemic Lupus Erythematosus (Sle) Drugs by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets – Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2027
• World Historic Review for Systemic Lupus Erythematosus (Sle) Drugs by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017
• World 15-Year Perspective for Systemic Lupus Erythematosus (Sle) Drugs by Geographic Region – Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2018 & 2027

III. MARKET ANALYSIS

GEOGRAPHIC MARKET ANALYSIS

IV. COMPETITION

• Total Companies Profiled: 41

For more information about this report visit https://www.researchandmarkets.com/r/wbz6dt

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

DUBLIN–(BUSINESS WIRE)–The “Systemic Lupus Erythematosus (Sle) Drugs – Global Market Trajectory & Analytics” report has been added to ResearchAndMarkets.com’s offering.

Global Systemic Lupus Erythematosus (Sle) Drugs Market to Reach US$264.5 Million by the Year 2027

Amid the COVID-19 crisis, the global market for Systemic Lupus Erythematosus (Sle) Drugs estimated at US$183.3 Million in the year 2020, is projected to reach a revised size of US$264.5 Million by 2027, growing at a CAGR of 5.4% over the period 2020-2027.

The U. S. Accounts for Over 29.5% of Global Market Size in 2020, While China is Forecast to Grow at a 5% CAGR for the Period of 2020-2027

The Systemic Lupus Erythematosus (Sle) Drugs market in the U. S. is estimated at US$54 Million in the year 2020. The country currently accounts for a 29.48% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$46. (Read more…)6 Million in the year 2027 trailing a CAGR of 5% through 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.1% and 4.3% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.4% CAGR while Rest of European market (as defined in the study) will reach US$46.6 Million by the year 2027.

The report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.

Competitors identified in this market include, among others:

• Amgen, Inc.
• Bristol-Myers Squibb Company
• GlaxoSmithKline PLC
• Immunomedics, Inc.
• Johnson & Johnson
• MedImmune LLC
• Merck Serono GmbH
• Sanofi SA
• Teva Pharmaceutical Industries Ltd.
• UCB SA

Key Topics Covered:

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

• Impact of Covid-19 and a Looming Global Recession
• Global Competitor Market Shares
• Systemic Lupus Erythematosus (Sle) Drugs Competitor Market Share Scenario Worldwide (in %): 2018E

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

• World Current & Future Analysis for Systemic Lupus Erythematosus (Sle) Drugs by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets – Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2027
• World Historic Review for Systemic Lupus Erythematosus (Sle) Drugs by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017
• World 15-Year Perspective for Systemic Lupus Erythematosus (Sle) Drugs by Geographic Region – Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2018 & 2027

III. MARKET ANALYSIS

GEOGRAPHIC MARKET ANALYSIS

IV. COMPETITION

• Total Companies Profiled: 41

For more information about this report visit https://www.researchandmarkets.com/r/wbz6dt

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

DUBLIN–(BUSINESS WIRE)–The “Systemic Lupus Erythematosus (Sle) Drugs – Global Market Trajectory & Analytics” report has been added to ResearchAndMarkets.com’s offering.

Global Systemic Lupus Erythematosus (Sle) Drugs Market to Reach US$264.5 Million by the Year 2027

Amid the COVID-19 crisis, the global market for Systemic Lupus Erythematosus (Sle) Drugs estimated at US$183.3 Million in the year 2020, is projected to reach a revised size of US$264.5 Million by 2027, growing at a CAGR of 5.4% over the period 2020-2027.

The U. S. Accounts for Over 29.5% of Global Market Size in 2020, While China is Forecast to Grow at a 5% CAGR for the Period of 2020-2027

The Systemic Lupus Erythematosus (Sle) Drugs market in the U. S. is estimated at US$54 Million in the year 2020. The country currently accounts for a 29.48% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$46. (Read more…)6 Million in the year 2027 trailing a CAGR of 5% through 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.1% and 4.3% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.4% CAGR while Rest of European market (as defined in the study) will reach US$46.6 Million by the year 2027.

The report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.

Competitors identified in this market include, among others:

• Amgen, Inc.
• Bristol-Myers Squibb Company
• GlaxoSmithKline PLC
• Immunomedics, Inc.
• Johnson & Johnson
• MedImmune LLC
• Merck Serono GmbH
• Sanofi SA
• Teva Pharmaceutical Industries Ltd.
• UCB SA

Key Topics Covered:

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

• Impact of Covid-19 and a Looming Global Recession
• Global Competitor Market Shares
• Systemic Lupus Erythematosus (Sle) Drugs Competitor Market Share Scenario Worldwide (in %): 2018E

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

• World Current & Future Analysis for Systemic Lupus Erythematosus (Sle) Drugs by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets – Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2027
• World Historic Review for Systemic Lupus Erythematosus (Sle) Drugs by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017
• World 15-Year Perspective for Systemic Lupus Erythematosus (Sle) Drugs by Geographic Region – Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2018 & 2027

III. MARKET ANALYSIS

GEOGRAPHIC MARKET ANALYSIS

IV. COMPETITION

• Total Companies Profiled: 41

For more information about this report visit https://www.researchandmarkets.com/r/wbz6dt

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900